

XENPOZYME™ (olipudase alfa-rpcp) INFUSION CHECKLIST FOR CLINICIANS¹

PATIENT NAME _____

DATE OF ADMINISTRATION _____

» COUNSEL PATIENTS AND CAREGIVERS

- Advise patients and caregivers that reactions related to the infusion may occur during and after XENPOZYME treatment, including anaphylactic reactions, other serious or severe hypersensitivity reactions, and IARs.
- Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and IARs and to seek medical care should signs and symptoms occur.
- XENPOZYME may cause embryo–fetal harm. Advise pregnant females and females of reproductive potential of the potential risk to the fetus. Advise female patients to inform their healthcare provider of a known or suspected pregnancy. *For more details, please see Section 8.1 in the XENPOZYME full Prescribing Information.*
- Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued. *For more details, please see Section 8.1, 8.3 in the XENPOZYME full Prescribing Information.*

» DETERMINE THE PATIENT'S PHASE IN THE DOSING SCHEDULE

PRIOR TO THE FIRST INFUSION:

- Consider administering pretreatment medication. Antihistamines, antipyretics, and/or corticosteroids may be given prior to XENPOZYME administration to reduce the risk of IARs. However, IARs may still occur in patients after receiving pretreatment.
- Ensure that baseline transaminase (ALT and AST) levels have been assessed within 1 month prior to treatment initiation.

DURING THE DOSE ESCALATION PHASE:

- Ensure the patient has not missed any doses since their prior infusion. In the event of missed doses, see guidance in the XENPOZYME full Prescribing Information.
- Determine the appropriate dose for patients by referring to Section 2.2, 2.3 in the XENPOZYME full Prescribing Information.
- Assess transaminase levels within 72 hours prior to any infusion during dose escalation, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following a missed dose.
 - » If transaminase levels are elevated above baseline and >2 times the ULN, the XENPOZYME dose can be adjusted (prior dose repeated or reduced) or treatment can be temporarily withheld until the liver transaminases return to the patient's baseline value.
 - » If either the baseline or pre–infusion transaminase level (during the dose escalation phase) is >2 times the ULN, repeat transaminase levels within 72 hours after the end of the infusion to monitor trends in liver enzyme elevations.

DURING THE MAINTENANCE PHASE:

- Ensure the patient has previously completed the dose escalation regimen prior to initiating the maintenance phase. The recommended target dose for the maintenance phase is 3 mg/kg.
- Ensure the patient has not missed any doses since their prior infusion. In the event of missed doses, see guidance in the XENPOZYME full Prescribing Information.
- If the treating physician has recommended, inform the patient that home infusions may be an option.
- Transaminase testing is recommended to be continued as part of routine clinical management.

ALT=alanine aminotransferase; AST=aspartate aminotransferase; IAR=infusion-associated reaction; ULN=upper limit of normal.

INDICATIONS AND USAGE

XENPOZYME™ (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPERSENSITIVITY REACTIONS

Hypersensitivity Reactions Including Anaphylaxis

Patients treated with XENPOZYME have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, XENPOZYME should be discontinued immediately, and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to XENPOZYME may be considered.

Please see [Important Safety Information](#) throughout and full [Prescribing Information](#), including **Boxed WARNING**, for complete details.

 **Xenpozyme™**
(olipudase alfa-rpcp)

INFUSION CHECKLIST (CONTINUED)¹

» XENPOZYME PREPARATION

- Determine the number of vials to be reconstituted based on the individual patient's weight and the prescribed dose; allow vials to reach room temperature.

Patient dose (mg)	Vials required
$\text{Patient weight (kg)} \times \text{dose (mg/kg)}$	$\frac{\text{Patient dose (mg)}}{20 \text{ mg/vial}}$

If the number of vials includes a fraction, round up to the next whole number.

- » Use actual body weight for patients with a BMI ≤ 30 . For patients with a BMI >30 , calculate adjusted body weight (kg) = (actual height in m)² \times 30.

» XENPOZYME RECONSTITUTION

Basic reconstitution steps are highlighted below. For more details, please see Section 2.6 in the XENPOZYME full Prescribing Information.

- Under aseptic conditions, reconstitute each vial of XENPOZYME with 5.1 mL of sterile water for injection, USP, by directing the diluent flow to the inside wall of the vial to avoid foaming.
 - » Gently roll and tilt vial(s) to reconstitute XENPOZYME and avoid foaming.
 - » Visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if the solution is discolored or if visible particulate matter is present.

» XENPOZYME DILUTION

- Withdraw the required volume of reconstituted solution and dilute to final volume with 0.9% sodium chloride injection, USP, in a syringe or infusion bag, depending on the volume of infusion, based on body weight and progress through dose escalation for adults or pediatric patients. For more details, please see Section 2.6, Table 4 in the XENPOZYME full Prescribing Information.
- Gently invert the syringe or the infusion bag to mix. Do not shake.

» XENPOZYME INFUSION

- Ensure appropriate medical support measures, including cardiopulmonary resuscitation equipment, are readily available during administration.
- Prior to administration, inspect the syringe or infusion bag for foaming. If foaming is present, let foam dissipate before administering XENPOZYME.
- Administer XENPOZYME at the infusion volumes and rates described in the XENPOZYME full Prescribing Information. Use an in-line low protein-binding 0.2- μm filter during administration.
- Do not infuse XENPOZYME in the same intravenous line with other products.

» POST-INFUSION

- After the infusion is complete, the infusion line should be flushed with 0.9% sodium chloride injection, USP, using the same infusion rate as the one used for the last part of the infusion.
- Vials are for single dose only. Discard any unused solution.

» PATIENT MONITORING

- During the dose escalation phase: Post-infusion testing of ALT and AST levels may be required to monitor patients if the pre-infusion levels were elevated and should be obtained within 72 hours after the end of infusion.
- Observe the patient closely for signs of IARs and hypersensitivity reactions during and for an appropriate period of time after the infusion, based on clinical judgment.
- In the event of a severe hypersensitivity reaction (e.g., anaphylaxis) or a severe IAR, immediately discontinue XENPOZYME administration and initiate appropriate medical treatment.
- In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding or slowing the infusion rate, and/or reducing the XENPOZYME dose. If dose is reduced, re-escalate following dose escalation according to the dose escalation regimens for adult and pediatric patients, as applicable.

» MAINTAINING A DOSING SCHEDULE

- Ensure that the patient or caregiver makes an appointment for the next infusion and understands the importance of adhering to a regular dosing schedule.
- Remind the patient and caregiver of support services available via CareConnectPSS®.

BMI=body mass index.

For more detailed instructions, please see the XENPOZYME full Prescribing Information and the XENPOZYME Dosing Guide.

Xenpozyme[™]
(olipudase alfa-rpcp)

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPERSENSITIVITY REACTIONS

Hypersensitivity Reactions Including Anaphylaxis

Patients treated with XENPOZYME have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, XENPOZYME should be discontinued immediately, and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to XENPOZYME may be considered.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis

Prior to XENPOZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration.

- If a *severe* hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering XENPOZYME following severe hypersensitivity reactions (including anaphylaxis).
- If a *mild or moderate* hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily withheld, and/or the XENPOZYME dose reduced.

Hypersensitivity reactions, including anaphylaxis, have been reported in olipudase alfa-treated patients.

- Hypersensitivity reactions in adults included urticaria, pruritus, erythema, rash, rash erythematous, eczema, angioedema, and erythema nodosum.
- Hypersensitivity reactions in pediatric patients included urticaria, pruritus, rash, erythema and localized edema.

Infusion-Associated Reactions

Antihistamines, antipyretics, and/or corticosteroids may be given prior to XENPOZYME administration to reduce the risk of infusion-associated reactions (IARs). However, IARs may still occur in patients after receiving pretreatment.

- If *severe* IARs occur, discontinue XENPOZYME immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering XENPOZYME following severe IARs.
- If a *mild or moderate* IAR occurs, the infusion rate may be slowed or temporarily withheld, and/or the XENPOZYME dosage may be reduced.

The most frequent IARs in:

- adult patients were headache, pruritus, vomiting and urticaria;
- pediatric patients were urticaria, erythema, headache, nausea, pyrexia, and vomiting.

An acute phase reaction (APR), an acute inflammatory response accompanied by elevations in inflammatory serum protein concentrations, was observed.

- Most of the APRs occurred at 48 hours post infusion during the dose escalation period.
- Elevations of C-reactive protein, calcitonin, and IL-6, and reduction of serum iron were observed.
- The most common clinical symptoms associated with APRs were pyrexia, vomiting, and diarrhea. APRs can be managed as other IARs.

Elevated Transaminases Levels

XENPOZYME may be associated with elevated transaminases (ALT, AST, or both) within 24 to 48 hours after infusion.

- Elevated transaminase levels were reported in patients during the XENPOZYME dose escalation phase in clinical trials.
- At the time of the next scheduled infusion, these elevated transaminase levels generally returned to levels observed prior to the XENPOZYME infusion.

To manage the risk of elevated transaminase levels, assess ALT and AST:

- within one month prior to initiation of XENPOZYME,
- within 72 hours prior to any infusion during dose escalation, which includes the first 3 mg/kg dose, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following a missed dose.
- **See full Prescribing Information for additional information on assessment and management of elevated transaminases.**

Upon reaching the recommended maintenance dose, transaminase testing is recommended to be continued as part of routine clinical management of ASMD.

Please see Important Safety Information throughout and full [Prescribing Information](#), including **Boxed WARNING**, for complete details.

 **Xenpozyme**[™]
(olipudase alfa-rpcp)

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS (CONTINUED)

Risk of Fetal Malformations During Dosage Initiation or Escalation in Pregnancy

XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended as it may lead to elevated sphingomyelin metabolite levels that may increase the risk of fetal malformations. The decision to continue or discontinue XENPOZYME maintenance dosing in pregnancy should consider the female's need for XENPOZYME, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal ASMD disease.

Verify pregnancy status in females of reproductive potential prior to initiating XENPOZYME treatment. Advise females of reproductive potential to use effective contraception during XENPOZYME treatment and for 14 days after the last dose if XENPOZYME is discontinued.

ADVERSE REACTIONS

- Most frequently reported adverse drug reactions in adults (incidence $\geq 10\%$) were headache, cough, diarrhea, hypotension, and ocular hyperemia.
- Most frequently reported adverse drug reactions in pediatric patients (incidence $\geq 20\%$) were pyrexia, cough, diarrhea, rhinitis, abdominal pain, vomiting, headache, urticaria, nausea, rash, arthralgia, pruritus, fatigue, and pharyngitis.

Please see full [Prescribing Information](#), including **Boxed WARNING**, for complete details.

Reference: 1. XENPOZYME. Prescribing Information. Sanofi; 2022.

sanofi

©2022 Genzyme Corporation. All rights reserved. Xenpozyme is owned by Genzyme Corporation. Sanofi and CareConnectPSS are registered trademarks of Sanofi or an affiliate.

MAT-US-2206674-v1.0-09/2022

Xenpozyme[™]
(olipudase alfa-rpcp)